ChanTest

Pharma

Drug developer ChanRx closes series A investment, hires CEO

Drug developer ChanRx has closed a series A round of investment that it will use to fund clinical trials of a pharmaceutical to treat atrial fibrillation. The Cleveland-area company, which was spun off from pharmaceutical testing firm ChanTest in 2006, didn’t specify the amount of the investment in a prepared statement. The round was led […]

News

“The Cities” awards: ChanTest named Healthcare Ally

Pharmaceutical testing company ChanTest has achieved several “firsts” in its 13 years, most related to the company’s drug discovery work with electricity-producing proteins called ion channels. Add another: The Cleveland-area company has been chosen as the first recipient of MedCity Media’s “The Cities” Healthcare Ally award, given to a service provider that has demonstrated extraordinary service […]

News

ChanRx to use $250K investment to reformulate a-fib drug

Updated 2:47 p.m., Aug. 5, 2010. Two-year-old drug development company ChanRx has received a $250,000 investment commitment from JumpStart Ventures, the investment arm of Northeast Ohio venture developer JumpStart Inc. ChanRx was spun off by ChanTest Corp. in Garfield Heights, Ohio, to develop small-molecule drugs — specifically, Vanoxerine — to treat atrial fibrillation, an increasingly […]